JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.21 -0.82

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.19

Max

1.22

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.7M -24M
EPS	-0.354
Angestellte	49
EBITDA	-5.3M -28M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+122.5% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-6.2M 75M
Vorheriger Eröffnungskurs	2.03
Vorheriger Schlusskurs	1.21

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Mai 2026, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1. Mai 2026, 20:40 UTC

Akquisitionen, Fusionen, Übernahmen

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1. Mai 2026, 18:37 UTC

Wichtige Markttreiber

Senseonic Shares Slide on Underwritten Offering Price

1. Mai 2026, 16:46 UTC

Wichtige Markttreiber

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2. Mai 2026, 19:57 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2. Mai 2026, 15:24 UTC

Ergebnisse

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2. Mai 2026, 12:46 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2. Mai 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. Mai 2026, 20:42 UTC

Ergebnisse

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1. Mai 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. Mai 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1. Mai 2026, 19:18 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1. Mai 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1. Mai 2026, 18:36 UTC

Ergebnisse

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1. Mai 2026, 18:35 UTC

Ergebnisse

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1. Mai 2026, 18:28 UTC

Ergebnisse

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1. Mai 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1. Mai 2026, 18:14 UTC

Akquisitionen, Fusionen, Übernahmen

Barclays Completes Acquisition of Best Egg

1. Mai 2026, 18:04 UTC

Ergebnisse

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1. Mai 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1. Mai 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1. Mai 2026, 17:30 UTC

Market Talk

Ergebnisse

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1. Mai 2026, 17:28 UTC

Market Talk

Ergebnisse

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1. Mai 2026, 17:21 UTC

Market Talk

Ergebnisse

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1. Mai 2026, 17:19 UTC

Market Talk

Wichtige Nachrichtenereignisse

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1. Mai 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1. Mai 2026, 16:23 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1. Mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

122.5% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 122.5%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.